These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
452 related articles for article (PubMed ID: 29475177)
1. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban. Verdoia M; Pergolini P; Barbieri L; Rolla R; Nardin M; Negro F; Suryapranata H; De Luca G; Thromb Res; 2018 Apr; 164():17-23. PubMed ID: 29475177 [TBL] [Abstract][Full Text] [Related]
2. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study. Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513 [TBL] [Abstract][Full Text] [Related]
3. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Galli M; Maggioni AP; Vassanelli C; Tavazzi L Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377 [TBL] [Abstract][Full Text] [Related]
4. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study. Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211 [TBL] [Abstract][Full Text] [Related]
5. Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting. Verdoia M; Schaffer A; Barbieri L; Cassetti E; Di Giovine G; Marino P; De Luca G; J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):100-5. PubMed ID: 24625566 [TBL] [Abstract][Full Text] [Related]
6. Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction. Xu LX; Chen KY; Liu T; Zheng XT; Jiao ZQ; Xu Y; Li G Cardiovasc Ther; 2016 Aug; 34(4):225-33. PubMed ID: 27133311 [TBL] [Abstract][Full Text] [Related]
7. Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. Verdoia M; Barbieri L; Schaffer A; Cassetti E; Di Giovine G; Bellomo G; Marino P; Sinigaglia F; De Luca G J Thromb Thrombolysis; 2014 Apr; 37(3):345-52. PubMed ID: 23793523 [TBL] [Abstract][Full Text] [Related]
8. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318 [TBL] [Abstract][Full Text] [Related]
17. Impact of the Polymorphism rs5751876 of the Purinergic Receptor ADORA2A on Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention. Negro F; Verdoia M; Nardin M; Suryapranata H; Kedhi E; Dudek D; De Luca G; J Atheroscler Thromb; 2021 Feb; 28(2):137-145. PubMed ID: 33342966 [TBL] [Abstract][Full Text] [Related]
18. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034 [TBL] [Abstract][Full Text] [Related]
19. Eosinophils count and periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions. Verdoia M; Schaffer A; Barbieri L; Sinigaglia F; Marino P; Suryapranata H; De Luca G; Atherosclerosis; 2014 Sep; 236(1):169-74. PubMed ID: 25055060 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]